Procalcitonin-based therapeutic strategy to reduce antibiotic use in patients after cardiac surgery: A randomized controlled trial

Introduction. Procalcitonin (PCT) is a thyroid gland prohormone, and its serum concentration is elevated in systemic bacterial infections. The diagnostic cut-off value of PCT in patients early after cardiac surgery remains unclear. Objective. We investigated whether procalcitonin-guidance could...

Full description

Bibliographic Details
Main Authors: Marinković Jelena, Borzanović Milorad, Ranković Aleksandra, Maravić-Stojković Vera, Laušević-Vuk Ljiljana, Jović Miomir
Format: Article
Language:English
Published: Serbian Medical Society 2011-01-01
Series:Srpski Arhiv za Celokupno Lekarstvo
Subjects:
Online Access:http://www.doiserbia.nb.rs/img/doi/0370-8179/2011/0370-81791112736M.pdf
id doaj-b7c7b36f703147ee899bb2b3bc5f2070
record_format Article
spelling doaj-b7c7b36f703147ee899bb2b3bc5f20702021-01-02T03:23:15ZengSerbian Medical SocietySrpski Arhiv za Celokupno Lekarstvo0370-81792011-01-0113911-1273674210.2298/SARH1112736MProcalcitonin-based therapeutic strategy to reduce antibiotic use in patients after cardiac surgery: A randomized controlled trialMarinković JelenaBorzanović MiloradRanković AleksandraMaravić-Stojković VeraLaušević-Vuk LjiljanaJović MiomirIntroduction. Procalcitonin (PCT) is a thyroid gland prohormone, and its serum concentration is elevated in systemic bacterial infections. The diagnostic cut-off value of PCT in patients early after cardiac surgery remains unclear. Objective. We investigated whether procalcitonin-guidance could reduce antibiotic usage safely. Methods. The prospective study included 205 patients who underwent open heart surgery. The patients were randomly assigned for procalcitonin-guided antibiotic treatment (PCT-group; n=102) or standard care (standard group; n=103). On the basis of serum procalcitonin concentrations, usage of antibiotics was encouraged (PCT≥0.5 ng/mL) or discouraged. Results. A relative risk of antibiotic exposure in the standard group compared with the PCT-group was 3.81 (95% CI=2.03-7.17; p<0.0001). The mean cost of antibiotics per patient in procalcitonin group was €193.3±636.6 vs. €372.1±841.1 (p=0.206) in the standard group, while the mean cost per hospital day was €8.0±18.4 vs. €17.8±36.3 (p=0.028). We found that non-infectious complications occurred in 40/102 vs. 41/103 (p=0.592) while infections appeared in 5/102 vs. 22/103 (p=0.001) cases. A statistically significant difference was observed in the treatment of urinary infections between PCT-group and standard group; 1/102 vs. 9/103 (p=0.016). In the PCT-group, the ICU stay was 5.74±11.49 days and in the standard group 6.97±11.61 (p=0.812). The hospital stay was 12.08±11.28 vs. 12.93±10.73 (p>0.05) days, respectively. Mortality rates were equal in both groups of patients (p=0.537). Conclusion. Procalcitonin-guided antibiotic treatment is safe and can significantly reduce the cost of postoperative care. Additionally, the antibiotic use during immediate postoperative course should be timely controlled and limited to documented bacterial infections.http://www.doiserbia.nb.rs/img/doi/0370-8179/2011/0370-81791112736M.pdfprocalcitoninantibioticsinflammatory mediatorscardiac surgery
collection DOAJ
language English
format Article
sources DOAJ
author Marinković Jelena
Borzanović Milorad
Ranković Aleksandra
Maravić-Stojković Vera
Laušević-Vuk Ljiljana
Jović Miomir
spellingShingle Marinković Jelena
Borzanović Milorad
Ranković Aleksandra
Maravić-Stojković Vera
Laušević-Vuk Ljiljana
Jović Miomir
Procalcitonin-based therapeutic strategy to reduce antibiotic use in patients after cardiac surgery: A randomized controlled trial
Srpski Arhiv za Celokupno Lekarstvo
procalcitonin
antibiotics
inflammatory mediators
cardiac surgery
author_facet Marinković Jelena
Borzanović Milorad
Ranković Aleksandra
Maravić-Stojković Vera
Laušević-Vuk Ljiljana
Jović Miomir
author_sort Marinković Jelena
title Procalcitonin-based therapeutic strategy to reduce antibiotic use in patients after cardiac surgery: A randomized controlled trial
title_short Procalcitonin-based therapeutic strategy to reduce antibiotic use in patients after cardiac surgery: A randomized controlled trial
title_full Procalcitonin-based therapeutic strategy to reduce antibiotic use in patients after cardiac surgery: A randomized controlled trial
title_fullStr Procalcitonin-based therapeutic strategy to reduce antibiotic use in patients after cardiac surgery: A randomized controlled trial
title_full_unstemmed Procalcitonin-based therapeutic strategy to reduce antibiotic use in patients after cardiac surgery: A randomized controlled trial
title_sort procalcitonin-based therapeutic strategy to reduce antibiotic use in patients after cardiac surgery: a randomized controlled trial
publisher Serbian Medical Society
series Srpski Arhiv za Celokupno Lekarstvo
issn 0370-8179
publishDate 2011-01-01
description Introduction. Procalcitonin (PCT) is a thyroid gland prohormone, and its serum concentration is elevated in systemic bacterial infections. The diagnostic cut-off value of PCT in patients early after cardiac surgery remains unclear. Objective. We investigated whether procalcitonin-guidance could reduce antibiotic usage safely. Methods. The prospective study included 205 patients who underwent open heart surgery. The patients were randomly assigned for procalcitonin-guided antibiotic treatment (PCT-group; n=102) or standard care (standard group; n=103). On the basis of serum procalcitonin concentrations, usage of antibiotics was encouraged (PCT≥0.5 ng/mL) or discouraged. Results. A relative risk of antibiotic exposure in the standard group compared with the PCT-group was 3.81 (95% CI=2.03-7.17; p<0.0001). The mean cost of antibiotics per patient in procalcitonin group was €193.3±636.6 vs. €372.1±841.1 (p=0.206) in the standard group, while the mean cost per hospital day was €8.0±18.4 vs. €17.8±36.3 (p=0.028). We found that non-infectious complications occurred in 40/102 vs. 41/103 (p=0.592) while infections appeared in 5/102 vs. 22/103 (p=0.001) cases. A statistically significant difference was observed in the treatment of urinary infections between PCT-group and standard group; 1/102 vs. 9/103 (p=0.016). In the PCT-group, the ICU stay was 5.74±11.49 days and in the standard group 6.97±11.61 (p=0.812). The hospital stay was 12.08±11.28 vs. 12.93±10.73 (p>0.05) days, respectively. Mortality rates were equal in both groups of patients (p=0.537). Conclusion. Procalcitonin-guided antibiotic treatment is safe and can significantly reduce the cost of postoperative care. Additionally, the antibiotic use during immediate postoperative course should be timely controlled and limited to documented bacterial infections.
topic procalcitonin
antibiotics
inflammatory mediators
cardiac surgery
url http://www.doiserbia.nb.rs/img/doi/0370-8179/2011/0370-81791112736M.pdf
work_keys_str_mv AT marinkovicjelena procalcitoninbasedtherapeuticstrategytoreduceantibioticuseinpatientsaftercardiacsurgeryarandomizedcontrolledtrial
AT borzanovicmilorad procalcitoninbasedtherapeuticstrategytoreduceantibioticuseinpatientsaftercardiacsurgeryarandomizedcontrolledtrial
AT rankovicaleksandra procalcitoninbasedtherapeuticstrategytoreduceantibioticuseinpatientsaftercardiacsurgeryarandomizedcontrolledtrial
AT maravicstojkovicvera procalcitoninbasedtherapeuticstrategytoreduceantibioticuseinpatientsaftercardiacsurgeryarandomizedcontrolledtrial
AT lausevicvukljiljana procalcitoninbasedtherapeuticstrategytoreduceantibioticuseinpatientsaftercardiacsurgeryarandomizedcontrolledtrial
AT jovicmiomir procalcitoninbasedtherapeuticstrategytoreduceantibioticuseinpatientsaftercardiacsurgeryarandomizedcontrolledtrial
_version_ 1724361239891542016